Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study

References

• JemalA, BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.2010721296855
   PubMed Web of Science ®Google Scholar
• McErleanA, GinsbergMS. Epidemiology of lung cancer. Semin Roentgenol. 2011;46(3):173–177. doi:10.1053/j.ro.2011.02.00221726701
   PubMed Web of Science ®Google Scholar
• Wasswa-KintuS, GanWQ, ManSF, ParePD, SinDD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005;60(7):570–575. doi:10.1136/thx.2004.03713515994265
   PubMed Web of Science ®Google Scholar
• WilsonDO, WeissfeldJL, BalkanA, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008;178(7):738–744. doi:10.1164/rccm.200803-435OC18565949
   PubMed Web of Science ®Google Scholar
• PowellHA, Iyen-OmofomanB, BaldwinDR, HubbardRB, TataLJ. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. J Thorac Oncol. 2013;8(4):e34–e35. doi:10.1097/JTO.0b013e31828950e3
   PubMed Web of Science ®Google Scholar
• SmithBM, PintoL, EzerN, SverzellatiN, MuroS, SchwartzmanK. Emphysema detected on computed tomography and risk of lung cancer: a systematic review and meta-analysis. Lung Cancer. 2012;77(1):58–63. doi:10.1016/j.lungcan.2012.02.01922437042
   PubMed Web of Science ®Google Scholar
• LoganathanRS, StoverDE, ShiW, VenkatramanE. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006;129(5):1305–1312. doi:10.1378/chest.129.5.130516685023
   PubMed Web of Science ®Google Scholar
• BuistAS, McBurnieMA, VollmerWM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–750. doi:10.1016/S0140-6736(07)61377-417765523
   PubMed Web of Science ®Google Scholar
• GaoYH, GuanWJ, LiuQ, et al. Impact of COPD and emphysema on survival of patients with lung cancer: a meta-analysis of observational studies. Respirology. 2016;21(2):269–279. doi:10.1111/resp.1266126567533
   PubMed Web of Science ®Google Scholar
• BuggeA, LundMB, BrunborgC, SolbergS, KongerudJ. Survival after surgical resection for lung cancer in patients with chronic obstructive pulmonary disease. Ann Thorac Surg. 2016;101(6):2125–2131. doi:10.1016/j.athoracsur.2015.12.05727016839
   PubMed Web of Science ®Google Scholar
• YoshidaY, KageH, MurakawaT, et al. Worse prognosis for stage IA lung cancer patients with smoking history and more severe chronic obstructive pulmonary disease. Ann Thorac Cardiovasc Surg. 2015;21(3):194–200. doi:10.5761/atcs.oa.14-0020025641032
   PubMed Web of Science ®Google Scholar
• LimJU, YeoCD, RheeCK, et al. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients. Int J Chron Obstruct Pulmon Dis. 2019;14:929–938. doi:10.2147/COPD.S19024431118602
   PubMed Web of Science ®Google Scholar
• LimJU, YeoCD, RheeCK, et al. Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients. Int J Chron Obstruct Pulmon Dis. 2018;13:2139–2146. doi:10.2147/COPD.S16737230034229
   PubMed Web of Science ®Google Scholar
• CoussensLM, WerbZ. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature0132212490959
   PubMed Web of Science ®Google Scholar
• BalkwillF, MantovaniA. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-011229684
   PubMed Web of Science ®Google Scholar
• GuX, SunS, GaoXS, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3430 patients. Sci Rep. 2016;6:23893. doi:10.1038/srep2389327025911
   PubMed Web of Science ®Google Scholar
• ZhangH, GaoL, ZhangB, ZhangL, WangC. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:22618. doi:10.1038/srep2261826939789
   PubMed Web of Science ®Google Scholar
• ZhaoQT, YuanZ, ZhangH, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3720 patients. Int J Cancer. 2016;139(1):164–170. doi:10.1002/ijc.3006026915723
   PubMed Web of Science ®Google Scholar
• WangW, BianC, XiaD, et al. Combining carcinoembryonic antigen and platelet to lymphocyte ratio to predict brain metastasis of resected lung adenocarcinoma patients. Biomed Res Int. 2017;2017:8076384.28642881
   PubMed Web of Science ®Google Scholar
• LinH, LuY, LinL, MengK, FanJ. Does chronic obstructive pulmonary disease relate to poor prognosis in patients with lung cancer?: a meta-analysis. Medicine (Baltimore). 2019;98(11):e14837. doi:10.1097/MD.000000000001483730882673
   PubMed Web of Science ®Google Scholar
• WangW, DouS, DongW, et al. Impact of COPD on prognosis of lung cancer: from a perspective on disease heterogeneity. Int J Chron Obstruct Pulmon Dis. 2018;13:3767–3776. doi:10.2147/COPD.S16804830538439
   PubMed Web of Science ®Google Scholar
• KumarP, LawS, SriramKB. Evaluation of platelet lymphocyte ratio and 90-day mortality in patients with acute exacerbation of chronic obstructive pulmonary disease. J Thorac Dis. 2017;9(6):1509–1516. doi:10.21037/jtd.2017.05.7728740663
   PubMed Web of Science ®Google Scholar
• YaoC, LiuX, TangZ. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2285–2290. doi:10.2147/COPD.S14176028814856
   PubMed Web of Science ®Google Scholar
• LimJU, YeoCD, KangHS, et al. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. PLoS One. 2018;13(7):e0200341. doi:10.1371/journal.pone.020034130005083
   PubMed Web of Science ®Google Scholar
• ShinSH, ParkHY, ImY, et al. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. Int J Cancer. 2019;145(9):2433–2439. doi:10.1002/ijc.3223530807641
   PubMed Web of Science ®Google Scholar
• BitonJ, OuakrimH, DechartresA, et al. Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade. Am J Respir Crit Care Med. 2018;198(7):928–940. doi:10.1164/rccm.201706-1110OC29518341
   PubMed Web of Science ®Google Scholar
• YeoCD, KimJW, KimKH, et al. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. Lung Cancer. 2013;81(2):207–212. doi:10.1016/j.lungcan.2013.04.02323726527
   PubMed Web of Science ®Google Scholar
• EisenhauerEA, TherasseP, BogaertsJ, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• MillerMR, HankinsonJ, BrusascoV, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
   PubMed Web of Science ®Google Scholar
• MorrisJF, KoskiA, JohnsonLC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis. 1971;103(1):57–67.5540840
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Res J. 2017;49:3. doi:10.1183/13993003.00214-2017
   Web of Science ®Google Scholar
• LimJU, YeoCD, KangHS, et al. Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion. Sci Rep. 2019;9(1):4721. doi:10.1038/s41598-019-41289-930886226
   PubMed Web of Science ®Google Scholar
• LinG-N, PengJ-W, Liu-P-P, LiuD-Y, Xiao-J-J, ChenX-Q. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. Asia Pac J Clin Oncol. 2017;13(5):e189–e194. doi:10.1111/ajco.1227325359280
   PubMed Web of Science ®Google Scholar
• DermanBA, MacklisJN, AzeemMS, et al. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017;17(1):141. doi:10.1186/s12885-017-3122-y28209123
   PubMed Web of Science ®Google Scholar
• GunayE, Sarinc UlasliS, AkarO, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation. 2014;37(2):374–380. doi:10.1007/s10753-013-9749-124078279
   PubMed Web of Science ®Google Scholar
• SzentkeresztyM, KomlosiZI, SzucsG, et al. Effect of COPD on inflammation, lymphoid functions and progression-free survival during first-line chemotherapy in advanced non-small cell lung cancer. Pathol Oncol Res. 2020;26(2):1117–1128.31090020
   PubMed Web of Science ®Google Scholar
• El-GazzarAG, KamelMH, ElbahnasyOKM, El-NaggarME. Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients. Expert Rev Respir Med. 2020;14(1):111–116. doi:10.1080/17476348.2019.167551731577911
   PubMed Web of Science ®Google Scholar
• KaplanKL, BroekmanMJ, ChernoffA, LesznikGR, DrillingsM. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood. 1979;53(4):604–618. doi:10.1182/blood.V53.4.604.604426909
   PubMed Web of Science ®Google Scholar
• FrancoAT, CorkenA, WareJ. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126(5):582–588. doi:10.1182/blood-2014-08-53158226109205
   PubMed Web of Science ®Google Scholar
• LeeTK, HornerRD, SilvermanJF, ChenYH, JennyC, ScarantinoCW. Morphometric and morphologic evaluations in stage III non-small cell lung cancers. Prognostic significance of quantitative assessment of infiltrating lymphoid cells. Cancer. 1989;63(2):309–316. doi:10.1002/1097-0142(19890115)63:2<309::AID-CNCR2820630218>3.0.CO;2-N2535956
   PubMed Web of Science ®Google Scholar
• GoodenMJ, de BockGH, LeffersN, DaemenT, NijmanHW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. doi:10.1038/bjc.2011.18921629244
   PubMed Web of Science ®Google Scholar
• HuangQ, DiaoP, LiCL, et al. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer. Medicine (Baltimore). 2020;99(4):e18607. doi:10.1097/MD.000000000001860731977852
   PubMed Web of Science ®Google Scholar